Breast cancer circulating biomarkers: advantages, drawbacks, and new insightsDaniele Generali, Chiara Senti, Paola Brambilla et al.|Tumor Biology|2015Cited by 47
Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunityAndrea Ravelli, Daniele Generali, James M. Reuben et al.|Expert Review of Anticancer Therapy|2015Cited by 12
A Phase II Study of Olaparib in Breast Cancer Patients: Biological Evaluation from a ‘Window of Opportunity’ TrialGiandomenico Roviello, Daniele Generali, Manuela Milani et al.|Future Oncology|2016Cited by 10
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast CancersGiandomenico Roviello, Daniele Generali, Manuela Milani et al.|Clinical Breast Cancer|2016Cited by 7